2 Information about atezolizumab

2 Information about atezolizumab

Marketing authorisation indication

Atezolizumab (Tecentriq, Roche) has a marketing authorisation for 'the treatment of adult patients with locally advanced or metastatic urothelial carcinoma after prior platinum-containing chemotherapy or who are considered cisplatin ineligible'.

Dosage in the marketing authorisation

1,200 mg by intravenous infusion every 3 weeks.


A 1,200 mg vial costs £3,807.69 excluding VAT.

The commercial arrangements included in the managed access agreement will be operationalised as a patient access scheme, agreed with the Department of Health. This scheme provides a simple discount to the list price of atezolizumab, with the discount applied at the point of purchase or invoice. The level of the discount is commercial in confidence. The Department of Health considered that this patient access scheme does not constitute an excessive administrative burden on the NHS.

  • National Institute for Health and Care Excellence (NICE)